<?xml version="1.0" encoding="UTF-8" ?>
	<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
	  <channel>
	  <copyright>Copyright 2009 Medical News Today</copyright>
	  <description>Latest Arthritis / Rheumatology News From Medical News Today.</description>
	  <link>http://www.medicalnewstoday.com/sections/arthritis/</link>
	  <title>Arthritis / Rheumatology News From Medical News Today</title>
	  <webMaster>admin&#064;medicalnewstoday.com  (MNT Admin)</webMaster>
	  <managingEditor>editors&#064;medicalnewstoday.com  (MNT Editors)</managingEditor>
	  <language>en-us</language><atom:link href="http://www.medicalnewstoday.com/rss/arthritis.xml" rel="self" type="application/rss+xml" /><item><title>Adeona Announces Publication Of Results Of 160 Patient Phase 2 Clinical Trial Of Oral DnaJP1 For Rheumatoid Arthritis</title><pubDate>Sun, 15 Nov 2009 01:00:00 PST</pubDate><link>http://www.medicalnewstoday.com/articles/170945.php</link><guid>http://www.medicalnewstoday.com/articles/170945.php</guid><description> Adeona Pharmaceuticals, Inc. (AMEX: AEN) announced the publication in the journal Arthritis &#38; Rheumatism of results of a 160&#45;patient, six&#45;month, double&#45;blind, placebo&#45;controlled Phase 2 clinical trial using the company's oral dnaJP1 for the treatment of rheumatoid arthritis (RA). The results of the study were originally presented at the 2008 American College of Rheumatology Annual Meeting. The study was sponsored by the National Institutes of Health (NIH).</description><category domain="http://www.medicalnewstoday.com/sections/arthritis/">Arthritis / Rheumatology</category></item><item><title>Judgement In Favour Of NICE On Judicial Review Of Abatacept For Rheumatoid Arthritis Guidance</title><pubDate>Tue, 10 Nov 2009 07:00:00 PST</pubDate><link>http://www.medicalnewstoday.com/articles/170417.php</link><guid>http://www.medicalnewstoday.com/articles/170417.php</guid><description>The High Court has ruled in favour of NICE by dismissing the application from Bristol Myers Squibb (BMS), the manufacturer of abatacept, for a judicial review of the NICE guidance on the use of abatacept for the treatment of rheumatoid arthritis.  In April 2008, NICE published final guidance which did not recommend abatacept as a treatment option for people with rheumatoid arthritis.</description><category domain="http://www.medicalnewstoday.com/sections/arthritis/">Arthritis / Rheumatology</category></item><item><title>MorphoSys Receives Regulatory Approval To Start Phase 1b/2a Clinical Trial For MOR103 Program</title><pubDate>Mon, 09 Nov 2009 05:00:00 PST</pubDate><link>http://www.medicalnewstoday.com/articles/170299.php</link><guid>http://www.medicalnewstoday.com/articles/170299.php</guid><description>Germany's Paul&#45;Ehrlich&#45;Institute Approves Clinical Trial in Rheumatoid Arthritis Patients   MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that it has received clearance from Germany's Paul&#45;Ehrlich&#45;Institute as well as a positive opinion from the ethics committees in Germ</description><category domain="http://www.medicalnewstoday.com/sections/arthritis/">Arthritis / Rheumatology</category></item><item><title>Link Between Childhood Physical Abuse And Arthritis</title><pubDate>Tue, 03 Nov 2009 05:00:00 PST</pubDate><link>http://www.medicalnewstoday.com/articles/169645.php</link><guid>http://www.medicalnewstoday.com/articles/169645.php</guid><description>Adults who had experienced physical abuse as children have 56 per cent higher odds of osteoarthritis compared to those who have not been abused, according to a new study by University of Toronto researchers.    University of Toronto researchers investigated the relationship between self&#45;reported childhood physical abuse and a diagnosis of osteoarthritis (OA).</description><category domain="http://www.medicalnewstoday.com/sections/arthritis/">Arthritis / Rheumatology</category></item><item><title>News From The Annals Of Internal Medicine, Nov. 3, 2009</title><pubDate>Tue, 03 Nov 2009 04:00:00 PST</pubDate><link>http://www.medicalnewstoday.com/articles/169578.php</link><guid>http://www.medicalnewstoday.com/articles/169578.php</guid><description>Early Releases    1. Report Questions Whether Family Health History Disclosure Improves Clinical Decision Making    Systematic collection of family history is a potentially important step in personalizing healthcare. Family health history can reveal important information about a patient, and may prompt specialist investigation or positive lifestyle changes.</description><category domain="http://www.medicalnewstoday.com/sections/hypertension/">Hypertension</category></item><item><title>New Tool To Accelerate Discovery Of Autoimmune Disease Mechanisms And Therapies</title><pubDate>Sat, 31 Oct 2009 00:00:00 PST</pubDate><link>http://www.medicalnewstoday.com/articles/169329.php</link><guid>http://www.medicalnewstoday.com/articles/169329.php</guid><description>Currently, 5 &#45; 8% of the U.S. population is afflicted with an autoimmune disease. Many of these are chronic and require life&#45;long care. Moreover, different autoimmune diseases aggregate within a single family, suggesting they are caused by disruptions in common biological pathways.    To help researchers investigate these common pathways, The Jackson Laboratory has published Pathways to Discovery: Autoimmune Diseases (</description><category domain="http://www.medicalnewstoday.com/sections/arthritis/">Arthritis / Rheumatology</category></item><item><title>Teriparatide Outperforms Alendronate In Treating Steroid&#45;Induced Osteoporosis</title><pubDate>Fri, 30 Oct 2009 00:00:00 PST</pubDate><link>http://www.medicalnewstoday.com/articles/169190.php</link><guid>http://www.medicalnewstoday.com/articles/169190.php</guid><description>A recent study determined glucocorticoid&#45;induced osteoporosis (OP) is now treatable with Teriparatide, a synthetic form of the human parathyroid hormone. Researchers found patients with glucocorticoid&#45;induced OP who were treated with teriparatide for 36 months had a greater increase in bone mineral density (BMD) and fewer new vertebral fractures than those treated with alendronate.</description><category domain="http://www.medicalnewstoday.com/sections/bones/">Bones / Orthopaedics</category></item><item><title>Anti&#45;Tumor Necrosis Factor Treatment Does Not Increase Cancer Risk In RA Patients</title><pubDate>Fri, 30 Oct 2009 00:00:00 PST</pubDate><link>http://www.medicalnewstoday.com/articles/169192.php</link><guid>http://www.medicalnewstoday.com/articles/169192.php</guid><description> A recent study by Swedish researchers found that rheumatoid arthritis (RA) patients did not experience an elevated cancer risk in the first 6 years after starting anti&#45;tumor necrosis factor (TNF) therapy. The research team, led by Johan Askling, M.D., Ph.D., from Karolinska University Hospital in Stockholm, Sweden assessed the short&#45;term and medium&#45;term cancer risk for RA patients using anti&#45;TNF therapies: infliximab, adalimumab, and etanercept.</description><category domain="http://www.medicalnewstoday.com/sections/arthritis/">Arthritis / Rheumatology</category></item><item><title>Tai Chi Exercise Reduces Knee Osteoarthritis Pain In The Elderly</title><pubDate>Fri, 30 Oct 2009 00:00:00 PST</pubDate><link>http://www.medicalnewstoday.com/articles/169194.php</link><guid>http://www.medicalnewstoday.com/articles/169194.php</guid><description>Researchers from Tufts University School of Medicine have determined that patients over 65 years of age with knee osteoarthritis (OA) who engage in regular Tai Chi exercise improve physical function and experience less pain. Tai Chi (Chuan) is a traditional style of Chinese martial arts that features slow, rhythmic movements to induce mental relaxation and enhance balance, strength, flexibility, and self&#45;efficacy.</description><category domain="http://www.medicalnewstoday.com/sections/arthritis/">Arthritis / Rheumatology</category></item><item><title>Link Between Pain Thresholds, Inflammation And Sleep Problems In Arthritis Patients</title><pubDate>Thu, 29 Oct 2009 05:00:00 PST</pubDate><link>http://www.medicalnewstoday.com/articles/169148.php</link><guid>http://www.medicalnewstoday.com/articles/169148.php</guid><description>Despite recent advances in anti&#45;inflammatory therapy, many rheumatoid arthritis (RA) patients continue to suffer from pain. Research published in BioMed Central's open access journal, Arthritis Research &#38; Therapy found that inflammation is associated with heightened pain sensitivity at joint sites, whereas increased sleep problems are associated with heightened pain sensitivity at both joint and non&#45;joint sites.</description><category domain="http://www.medicalnewstoday.com/sections/arthritis/">Arthritis / Rheumatology</category></item><item><title>The Why And The How Of The Benefits Of Fish Oils</title><pubDate>Thu, 29 Oct 2009 05:00:00 PST</pubDate><link>http://www.medicalnewstoday.com/articles/169153.php</link><guid>http://www.medicalnewstoday.com/articles/169153.php</guid><description>New research from Queen Mary, University of London and Harvard Medical School has revealed precisely why taking fish oils can help with conditions like rheumatoid arthritis.    In a paper published in Nature*, researchers describe how the body converts an ingredient found in fish oils into another chemical called Resolvin D2 and how this chemical reduces the inflammation that leads to a variety of diseases.</description><category domain="http://www.medicalnewstoday.com/sections/nutrition-agriculture/">Nutrition / Diet</category></item><item><title>Advancing Personalized Medicine In Rheumatoid Arthritis</title><pubDate>Mon, 26 Oct 2009 00:00:00 PST</pubDate><link>http://www.medicalnewstoday.com/articles/168627.php</link><guid>http://www.medicalnewstoday.com/articles/168627.php</guid><description>The University of Alabama at Birmingham (UAB) is spearheading an effort to create a national database and repository to enable researchers to identify predictors of effectiveness of various treatments for rheumatoid arthritis (RA). RA is the most common type of inflammatory arthritis. Many effective medications exist, but they vary greatly in cost and side effects, and there is no way to predict which drug will work best on an individual.    A two&#45;year, $3.</description><category domain="http://www.medicalnewstoday.com/sections/arthritis/">Arthritis / Rheumatology</category></item><item><title>UAB Creates National Network To Advance Personalized Medicine In Rheumatoid Arthritis</title><pubDate>Sun, 25 Oct 2009 00:00:00 PST</pubDate><link>http://www.medicalnewstoday.com/articles/168564.php</link><guid>http://www.medicalnewstoday.com/articles/168564.php</guid><description>The University of Alabama at Birmingham (UAB) is spearheading an effort to create a national database and repository to enable researchers to identify predictors of effectiveness of various treatments for rheumatoid arthritis (RA). RA is the most common type of inflammatory arthritis. Many effective medications exist, but they vary greatly in cost and side effects, and there is no way to predict which drug will work best on an individual.   A two&#45;year, $3.</description><category domain="http://www.medicalnewstoday.com/sections/arthritis/">Arthritis / Rheumatology</category></item><item><title>TNF&#45;Alpha Inhibitors Will Continue To Dominate First&#45; And Second&#45;Line Biologic Therapy For The Treatment Of Rheumatoid Arthritis Through 2011</title><pubDate>Fri, 23 Oct 2009 03:00:00 PST</pubDate><link>http://www.medicalnewstoday.com/articles/168425.php</link><guid>http://www.medicalnewstoday.com/articles/168425.php</guid><description>Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that tumor necrosis factor (TNF)&#45;alpha inhibitors will continue to dominate first&#45; and second&#45;line biologic therapy for the treatment of rheumatoid arthritis in the U</description><category domain="http://www.medicalnewstoday.com/sections/arthritis/">Arthritis / Rheumatology</category></item><item><title>Therapeutic Advances In Musculoskeletal Disease Launched By SAGE</title><pubDate>Fri, 23 Oct 2009 01:00:00 PST</pubDate><link>http://www.medicalnewstoday.com/articles/168398.php</link><guid>http://www.medicalnewstoday.com/articles/168398.php</guid><description>SAGE has announced the launch of Therapeutic Advances in Musculoskeletal Disease, the latest in SAGE's highly&#45;regarded Therapeutic Advances series.    Therapeutic Advances in Musculoskeletal Disease is for all professionals concerned with research into, and the practice of, musculoskeletal disease and is a forum for all views on related subjects. The journal offers rapid peer review and publication, with manuscripts published online within 7 weeks of acceptance.</description><category domain="http://www.medicalnewstoday.com/sections/arthritis/">Arthritis / Rheumatology</category></item><item><title>CombinatoRx'S Synavive (CRx&#45;102) Maintains Efficacy Throughout 12 Month Phase 2 Knee OA Extension Trial</title><pubDate>Fri, 23 Oct 2009 00:00:00 PST</pubDate><link>http://www.medicalnewstoday.com/articles/168376.php</link><guid>http://www.medicalnewstoday.com/articles/168376.php</guid><description>CombinatoRx, Incorporated (NASDAQ: CRXX) announced the results of a 12 month knee osteoarthritis (OA) Phase 2 extension trial for Synavive&#x2122; (CRx&#45;102) at the American College of Rheumatology (ACR) 2009 Annual Meeting in Philadelphia. The data demonstrated that Synavive&#45;treated subjects maintained efficacy levels throughout the 12 month extension trial.</description><category domain="http://www.medicalnewstoday.com/sections/arthritis/">Arthritis / Rheumatology</category></item><item><title>Tocilizumab Shows Sustained Efficacy In Rheumatoid Arthritis</title><pubDate>Fri, 23 Oct 2009 00:00:00 PST</pubDate><link>http://www.medicalnewstoday.com/articles/168415.php</link><guid>http://www.medicalnewstoday.com/articles/168415.php</guid><description>PHILADELPHIA &#45; Investigators are reporting that tolicizumab is an effective, long&#45;term treatment option in multiple subgroups of rheumatoid arthritis (RA) patients.     These include patients who have an inadequate response to disease&#45;modifying anti&#45;rheumatic drugs (DMARD&#45;IR), patients who have an inadequate response to anti&#45;TNF inhibitors (TNF&#45;IR), and patients who have not failed methotrexate.</description><category domain="http://www.medicalnewstoday.com/sections/arthritis/">Arthritis / Rheumatology</category></item><item><title>Growing Cartilage From Stem Cells</title><pubDate>Thu, 22 Oct 2009 06:00:00 PST</pubDate><link>http://www.medicalnewstoday.com/articles/168333.php</link><guid>http://www.medicalnewstoday.com/articles/168333.php</guid><description>    Damaged knee joints might one day be repaired with cartilage grown from stem cells in a laboratory, based on research by Professor Kyriacos Athanasiou, chair of the UC Davis Department of Biomedical Engineering and his colleagues.    Using adult stem cells from bone marrow and skin as well as human embryonic stem cells, Athanasiou and his group have already grown cartilage tissue in the lab.</description><category domain="http://www.medicalnewstoday.com/sections/stem_cell/">Stem Cell Research</category></item><item><title>Important New Rheumatology Resource Unveiled</title><pubDate>Thu, 22 Oct 2009 03:00:00 PST</pubDate><link>http://www.medicalnewstoday.com/articles/168260.php</link><guid>http://www.medicalnewstoday.com/articles/168260.php</guid><description>A comprehensive account of the most important advances in rheumatology research from the past decade has been published in BioMed Central's open access journal Arthritis Research and Therapy (AR&#38;T).</description><category domain="http://www.medicalnewstoday.com/sections/arthritis/">Arthritis / Rheumatology</category></item><item><title>FDA Approves New Test To Aid In The Diagnosis Of Rheumatoid Arthritis</title><pubDate>Wed, 21 Oct 2009 22:00:00 PST</pubDate><link>http://www.medicalnewstoday.com/articles/168195.php</link><guid>http://www.medicalnewstoday.com/articles/168195.php</guid><description>An important assay used to aid in the diagnosis of rheumatoid arthritis (RA) will soon be available on Abbott's ARCHITECT immunoassay analyzers. The FDA has granted 510(k) clearance for an antibody cyclic&#45;citrulinated peptide, or anti&#45;CCP assay, to run on the world class systems.    Many patients with RA develop an immune response against proteins containing citrulline long before they present symptoms of the disease.</description><category domain="http://www.medicalnewstoday.com/sections/arthritis/">Arthritis / Rheumatology</category></item><item><title>Updated Data From Randomized Controlled Phase II Study Evaluating Oral Apremilast In Psoriatic Arthritis Demonstrates Sustained Response At Six Months</title><pubDate>Tue, 20 Oct 2009 22:00:00 PST</pubDate><link>http://www.medicalnewstoday.com/articles/168006.php</link><guid>http://www.medicalnewstoday.com/articles/168006.php</guid><description>Celgene Corporation (NASDAQ: CELG) announced that updated results of a phase II, multi&#45;center, randomized, double&#45;blind, placebo&#45;controlled, three&#45;arm study of apremilast in adult patients with psoriatic arthritis (CC&#45;10004&#45;PSA&#45;001) were presented today at the American College of Rheumatology (ACR) 2009 annual meeting in Philadelphia, PA.</description><category domain="http://www.medicalnewstoday.com/sections/arthritis/">Arthritis / Rheumatology</category></item><item><title>Winston Laboratories, Inc. Receives Notice Of Non&#45;Compliance In Canada For Its New Drug Submission Of CIVANEX To Treat Osteoarthritis</title><pubDate>Tue, 20 Oct 2009 21:00:00 PST</pubDate><link>http://www.medicalnewstoday.com/articles/168004.php</link><guid>http://www.medicalnewstoday.com/articles/168004.php</guid><description>Winston Laboratories, Inc. ("Winston Labs"), a wholly&#45;owned subsidiary of Winston Pharmaceuticals, Inc. (OTC BB: WPHM) today announced that it has received a Notice of Non&#45;compliance ("NON") from the Therapeutics Drug Directorate, Health Canada (the "Directorate") for its New Drug Submission (NDS) for CIVANEX (zucapsaicin cream 0.075%) for the treatment of the signs and symptoms of osteoarthritis.</description><category domain="http://www.medicalnewstoday.com/sections/bones/">Bones / Orthopaedics</category></item><item><title>United States Bone And Joint Decade Announces Conference Program</title><pubDate>Tue, 20 Oct 2009 02:00:00 PST</pubDate><link>http://www.medicalnewstoday.com/articles/167937.php</link><guid>http://www.medicalnewstoday.com/articles/167937.php</guid><description>The United States Bone and Joint Decade announced an unparalleled program for its 2009 Global Network Conference to be held in Washington, D.C., Wednesday, October 21&#45;Saturday, October 24.</description><category domain="http://www.medicalnewstoday.com/sections/bones/">Bones / Orthopaedics</category></item><item><title>CEL&#45;SCI Presents Data At American College Of Rheumatology Conference Which Suggests That CEL&#45;2000 Has Potential To Slow Damage</title><pubDate>Tue, 20 Oct 2009 01:00:00 PST</pubDate><link>http://www.medicalnewstoday.com/articles/167898.php</link><guid>http://www.medicalnewstoday.com/articles/167898.php</guid><description>CEL&#45;SCI Corporation (NYSE Amex: CVM) announced the presentation of new rheumatoid arthritis data at the American College of Rheumatology's annual meeting in Philadelphia, PA. The data, presented by Dr.</description><category domain="http://www.medicalnewstoday.com/sections/arthritis/">Arthritis / Rheumatology</category></item><item><title>Patients Taking VIMOVO(TM) Showed A Decrease In Incidence Of NSAID&#45;Associated Ulcers</title><pubDate>Tue, 20 Oct 2009 01:00:00 PST</pubDate><link>http://www.medicalnewstoday.com/articles/167899.php</link><guid>http://www.medicalnewstoday.com/articles/167899.php</guid><description>AstraZeneca (NYSE: AZN) and POZEN Inc. (Nasdaq: POZN) announced pivotal data from two POZEN clinical trials that were presented at the American College of Rheumatology (ACR) 2009 Annual Scientific Meeting in Philadelphia, PA.</description><category domain="http://www.medicalnewstoday.com/sections/gastrointestinal/">GastroIntestinal / Gastroenterology</category></item></channel></rss>